10:33 AM EST - Oncolytics Biotech Inc : Announced it has concluded enrollment in the GOBLET study, having generated the necessary clinical and translational data to inform its next phase of development. With sufficient cash on hand to execute near-term milestones, the Company will now focus its efforts and resources on registrational and registration-enabling studies in squamous cell anal cancer and metastatic colorectal cancer. Oncolytics Biotech Inc
shares N.ONCY are trading up $0.03 at $1.09.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7748280220753183
